Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 416

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: Asystematic review and mixed‐treatment comparison analysis

Open access
Htike, Zin Z., Zaccardi, Francesco, Papamargaritis, Dimitris, Webb, David R., Khunti, Kamlesh, Davies, Melanie J.·2017·Diabetes, Obesity and Metabolism

Abstract

Aims: To compare efficacy and safety of glucagon‐like peptide‐1 receptor agonists ( GLP‐1RAs ) in people with type 2 diabetes. Materials and methods: We electronically searched, up to J une 3, 2016, published randomized clinical trials lasting between 24 and 32 weeks that compared a GLP‐1RA (albiglutide, dulaglutide, twice‐daily exenatide and once‐weekly exenatide, liraglutide, lixisenatide, semaglutide and taspoglutide) with placebo or another GLP‐1RA . Data on cardiometabolic and safety outcomes were analysed using a mixed‐treatment comparison meta‐analysis. Results: A total of 34 trials (14 464 participants) met the inclusion criteria; no published data for semaglutide were available. Compared with placebo, all GLP‐1RAs reduced glycated haemoglobin ( HbA1c ) and fasting plasma glucose ( FPG ) levels (reductions ranged from −0.55% and −0.73 mmol/ L , respectively, for lixisenatide to −1.21% and −1.97 mmol/ L , respectively, for dulaglutide). There were no differences within short‐acting (twice‐daily exenatide and lixisenatide) or long‐acting (albiglutide, dulaglutide, once‐weekly exenatide, liraglutide and taspoglutide) groups. Compared with twice‐daily exenatide, dulaglutide treatment was associated with the greatest HbA1c and FPG reduction (0.51% and 1.04 mmol/ L , respectively), followed by liraglutide (0.45% and 0.93 mmol/ L , respectively) and once‐weekly exenatide (0.38% and 0.85 mmol/ L , respectively); similar reductions were found when these 3 agents were compared with lixisenatide. Compared with placebo, all GLP‐1RAs except albiglutide reduced weight and increased the risk of hypoglycaemia and gastrointestinal side effects, and all agents except dulaglutide and taspoglutide reduced systolic blood pressure. When all GLP‐1RAs were compared with each other, no clinically meaningful differences were observed in weight loss, blood pressure reduction or hypoglycaemia risk. Albiglutide had the lowest risk of nausea and diarrhoea and once‐weekly exenatide the lowest risk of vomiting. Conclusions: The RCTs in the present analysis show that all GLP‐1RAs improve glycaemic control, reduce body weight and increase the risk of adverse gastrointestinal symptoms compared with placebo. Although there were no differences when short‐acting agents were compared with each other or when long‐acting agents were compared with each other, dulaglutide, liraglutide and once‐weekly exenatide were superior to twice‐daily exenatide and lixisenatide at lowering HbA1c and FPG levels. There were no differences in hypoglycaemia between these 3 agents, whilst once‐weekly exenatide had the lowest risk of vomiting. These results, along with patient's preferences and individualized targets, should be considered when selecting a GLP‐1RA .

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12849

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

See all 416

Metadata

Authors
Htike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2017-02-17
Volume
19
Issue
4
Pages
524-536
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2563047690
Cited by
416
References
68
FWCI
7.07
Type
journal article
Language
en
Open access
bronze
Funders
National Institute for Health Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: Asystematic review and mixed‐treatment comparison analysis. https://app.cochat.ai/papers/10.1111/dom.12849
The paper
Htike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017). Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: Asystematic review and mixed‐treatment comparison analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12849

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.